Upgrade to SI Premium - Free Trial

ProQR (PRQR)

1.50 -0.03 (1.96%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V. June 3, 2026 5:25 PM - SEC Filing Form 4 ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke June 3, 2026 4:01 PM - SEC Filing Form 6-K ProQR Therapeutics N.V. For: Jun 02 June 2, 2026 4:02 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke June 2, 2026 4:02 PM - SEC Filing ProQR Therapeutics N.V. (PRQR) Reiterated at Market Outperform by Citizens May 27, 2026 5:52 AM - StreetInsider Form 6-K ProQR Therapeutics N.V. For: Mar 31 May 12, 2026 7:01 AM - SEC Filing ProQR Announces First Quarter 2026 Operating and Financial Results May 12, 2026 7:00 AM - Globe NewsWire Form 6-K ProQR Therapeutics N.V. For: May 12 May 12, 2026 7:00 AM - SEC Filing ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform May 11, 2026 8:00 AM - Globe NewsWire Form 6-K ProQR Therapeutics N.V. For: May 04 May 4, 2026 8:06 AM - SEC Filing ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 May 4, 2026 8:00 AM - StreetInsider Form 6-K ProQR Therapeutics N.V. For: Apr 30 April 30, 2026 8:13 AM - SEC Filing ProQR nominates Boehringer Ingelheim executive to board of directors April 30, 2026 8:01 AM - StreetInsider ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors April 30, 2026 8:00 AM - Globe NewsWire Form 6-K ProQR Therapeutics N.V. For: Apr 08 April 8, 2026 4:07 PM - SEC Filing ProQR details pipeline expansion with multiple clinical catalysts April 8, 2026 4:00 PM - StreetInsider ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event April 8, 2026 4:00 PM - StreetInsider Form 6-K ProQR Therapeutics N.V. For: Apr 08 April 8, 2026 8:09 AM - SEC Filing ProQR partners with Ginkgo Bioworks and forms AI advisory board April 8, 2026 8:01 AM - StreetInsider ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board April 8, 2026 8:00 AM - Globe NewsWire Form 6-K ProQR Therapeutics N.V. For: Mar 25 March 25, 2026 8:02 AM - SEC Filing ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 March 25, 2026 8:00 AM - StreetInsider Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Valerio Domenico March 18, 2026 4:10 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Platenburg Gerardus Johannes March 18, 2026 4:10 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Maier Martin Alexander March 18, 2026 4:09 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Lawton Alison Frances March 18, 2026 4:06 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Hom Dennis March 18, 2026 4:05 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: HEGGIE THERESA March 18, 2026 4:05 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Filius Bart March 18, 2026 4:03 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: de Boer Daniel Anton March 18, 2026 4:03 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Carreno-Gomez Begona March 18, 2026 4:02 PM - SEC Filing Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Shannon James Samuel March 18, 2026 4:01 PM - SEC Filing ProQR Therapeutics (PRQR) Reiterated at Market Outperform by Citizens on AX-0810 Potential March 13, 2026 6:28 AM - StreetInsider Oppenheimer Starts ProQR Therapeutics N.V. (PRQR) at Outperform March 12, 2026 7:45 AM - StreetInsider Form 20-F ProQR Therapeutics N.V. For: Dec 31 March 12, 2026 7:23 AM - SEC Filing Form 6-K ProQR Therapeutics N.V. For: Mar 12 March 12, 2026 7:00 AM - SEC Filing ProQR Announces Year End 2025 Operating and Financial Results March 12, 2026 7:00 AM - StreetInsider Lyell Immunopharma closes $50 million funding, names new CFO March 9, 2026 8:00 AM - StreetInsider Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer  March 9, 2026 8:00 AM - StreetInsider Full Article List